David Gershenson Gynecologic oncologist, researcher
Gershenson, David M. (David Marc), 1946-
Gershenson, David Marc, 1946-
Gershenson, David M., 1946-
Gershenson, David Marc
Gershenson, David M.
Gershenson, David M. (David Marc)
VIAF ID: 63023787 (Personal)
Permalink: http://viaf.org/viaf/63023787
Preferred Forms
- 100 0 _ ‡a David Gershenson ‡c Gynecologic oncologist, researcher
-
- 100 1 _ ‡a Gershenson, David M. ‡d 1946-
- 100 1 _ ‡a Gershenson, David M. ‡q (David Marc)
-
-
- 100 1 _ ‡a Gershenson, David M. ‡q (David Marc), ‡d 1946-
-
-
-
-
- 100 1 _ ‡a Gershenson, David Marc
-
-
- 100 1 _ ‡a Gershenson, David Marc ‡d 1946-
- 100 1 _ ‡a Gershenson, David Marc, ‡d 1946-
4xx's: Alternate Name Forms (12)
Works
Title | Sources |
---|---|
Clinical Conference on Cancer (29th : 1985 : M.D. Anderson Hospital and Tumor Institute at Houston). Gynecologic cancer, 1987: | |
Fujinka gan | |
Ginecologia operatoria | |
Gynecologic cancer : controversies in management | |
Gynecologic cancer : diagnosis and treatment strategies | |
n86040743 | |
Operative gynecology | |
Ovarian and extraovarian endometriosis-associated cancer | |
Ovarian cancer. Clinical practice guidelines in oncology | |
Ovarian cancer, version 3.2012. | |
Ovarian intestinal type mucinous borderline tumors: are we ready for a nomenclature change? | |
Ovarian Yolk Sac Tumors; Does Age Matter? | |
Overexpression of the centrosomal protein Aurora-A kinase is associated with poor prognosis in epithelial ovarian cancer patients. | |
Patient preferences regarding side effects of chemotherapy for ovarian cancer: do they change over time? | |
Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. | |
Patterns of metastasis in sex cord-stromal tumors of the ovary: can routine staging lymphadenectomy be omitted? | |
Pediatric and Adolescent Extracranial Germ Cell Tumors: The Road to Collaboration | |
Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. | |
Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer | |
Peritoneal lesions in guinea pigs treated with hormones | |
Phase Ib/II study of weekly topotecan and daily gefitinib in patients with platinum resistant ovarian, peritoneal, or fallopian tube cancer | |
Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma | |
Poor survival with wild-type TP53 ovarian cancer? | |
Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 Study | |
Preoperative factors predicting survival after secondary cytoreduction for recurrent ovarian cancer | |
Preoperative serum tissue factor levels are an independent prognostic factor in patients with ovarian carcinoma | |
Prevalence of lymph node metastasis in primary mucinous carcinoma of the ovary | |
Principles and practice of clinical gynecology | |
The prognostic significance of pre- and post-treatment CA-125 in grade 1 serous ovarian carcinoma: a gynecologic Oncology Group study. | |
Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations. | |
Prophylactic Surgery to Reduce the Risk of Gynecologic Cancers in the Lynch Syndrome | |
Prospective evaluation of insulin resistance among endometrial cancer patients | |
Prospective multicenter randomized intermediate biomarker study of oral contraceptive versus depo-provera for prevention of endometrial cancer in women with Lynch syndrome | |
Prospective study of the correlation between postoperative computed tomography scan and primary surgeon assessment in patients with advanced ovarian, tubal, and peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residu | |
Quality of life and sexual functioning in cervical cancer survivors. | |
Quantification of total plasma cell-free DNA in ovarian cancer using real-time PCR. | |
Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum‐resistant ovarian cancer | |
Rare Gynecologic Tumors: Coming of Age | |
RAS promotes tumorigenesis through genomic instability induced by imbalanced expression of Aurora-A and BRCA2 in midbody during cytokinesis. | |
The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent | |
Reduced progression of endometrial hyperplasia with oral mTOR inhibition in the Pten heterozygote murine model. | |
Reproductive and sexual function after platinum-based chemotherapy in long-term ovarian germ cell tumor survivors: a Gynecologic Oncology Group Study | |
Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential | |
Response to re-challenge of a MEK inhibitor in a patient with recurrent low-grade serous carcinoma of the peritoneum | |
Risk factors for young premenopausal women with endometrial cancer | |
The Role of GDF15 in Regulating the Canonical Pathways of the Tumor Microenvironment in Wild-Type p53 Ovarian Tumor and Its Response to Chemotherapy | |
Role of hysterectomy and lymphadenectomy in the management of early-stage borderline ovarian tumors | |
Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer. | |
The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance | |
The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer | |
Salvage chemotherapy for gestational trophoblastic neoplasia: Utility or futility? | |
Sarcomatoid carcinoma of the cervix. | |
SEER data: perspective at 10,000 feet | |
Selected highlights from the 5th International Conference on Ovarian Cancer. Houston, TX, USA, 1-4 December 2004. | |
Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis | |
Selective activation of ceruloplasmin promoter in ovarian tumors: potential use for gene therapy | |
Serous carcinoma of the ovary, fallopian tube, or peritoneum presenting as lymphadenopathy | |
Significance of lymph node ratio on survival of women with borderline ovarian tumors | |
Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis | |
Specific keynote: molecular therapeutics in ovarian cancer | |
Stage IIIC ovarian/peritoneal serous carcinoma: a heterogeneous group of patients with different prognoses. | |
STK15 F31I polymorphism is associated with increased uterine cancer risk: a pilot study. | |
Stress hormone-mediated invasion of ovarian cancer cells | |
Subcellular localization of p27kip1 expression predicts poor prognosis in human ovarian cancer. | |
Successful pregnancy following chemotherapy in a survivor of small cell carcinoma of the ovary, hypercalcemic type (SCCOHT): A case report and review of literature | |
Summary of the 2014 MD Anderson International Meeting in Gynecologic Oncology: emerging therapies in gynecologic cancer. | |
Synchronous primary cancers of the endometrium and ovary: a single institution review of 84 cases | |
Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer | |
Time for action: a "sea change" in treatment strategies for rare types of epithelial ovarian cancer | |
Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial | |
Uptake and outcomes of neoadjuvant chemotherapy among US patients with less common epithelial ovarian carcinomas | |
The use of cytokeratin 7 and EMA in differentiating ovarian yolk sac tumors from endometrioid and clear cell carcinomas | |
婦人科癌 |